Multiple Sclerosis and Related Disorders

Article	Citations
How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms	108
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States	80
Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report	77
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis	72
Long COVID or post COVID-19 syndrome	65
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review	64
Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study	60
Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review	57
Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis	56
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study	53
COVID-19 in ocrelizumab-treated people with multiple sclerosis	52
OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis	48
MOG-associated encephalitis following SARS-COV-2 infection	47
The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance	47
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021	44
A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis	43
Autoimmune encephalitis associated with COVID-19: A systematic review	42
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?	42
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis	42
Effectiveness of Virtual Reality Rehabilitation in Persons with Multiple Sclerosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials	40
Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases	39
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England	38
Fear of falling and falls in people with multiple sclerosis: A literature review	38
Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review	38
Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients	37

Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways	37
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies	37
COVID-19 vaccine associated demyelination & its association with MOG antibody	37
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis	37
COVID-19 and emerging spinal cord complications: A systematic review	36
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis	36
Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy	36
Multiple sclerosis and aging: comorbidity and treatment challenges	36
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America	35
The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity	34
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis	34
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis	33
The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades	33
Social cognition in multiple sclerosis and its subtypes: A meta-analysis	33
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects	33
T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers	32
Anti-MOG associated disorder–Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD–A single-center experience	32
Multiple sclerosis incidence: A systematic review of change over time by geographical region	31
Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series	31
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab	31
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases	31
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis	31
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19	31
Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review	30
Depression in multiple sclerosis: Is one approach for its management enough?	30
Long-term dynamics of multiple sclerosis iron rim lesions	30
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis	30
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness	29
Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis	29
Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic	28
Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population	28
Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration	28
Tired of not knowing what that fatigue score means? Normative data of the Modified Fatigue Impact Scale (MFIS)	28
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?	27
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience	27
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients	27
Early predictors of conversion to secondary progressive multiple sclerosis	27
Artificial intelligence in the diagnosis of multiple sclerosis: A systematic review	27
Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey	26
Vaccine hesitancy among people with multiple sclerosis	26
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data	26
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study	26
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab	26
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience	26
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial	26
Use of natalizumab in persons with multiple sclerosis: 2022 update	26
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia	26
Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies	25
Effects on gait and balance of home-based active video game interventions in persons with multiple sclerosis: A systematic review	25
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar	25

Details and outcomes of a large cohort of MOG-IgG associated optic neuritis	25
Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis	25
Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics	24
High or increasing serum NfL is predictive of impending multiple sclerosis relapses	24
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters	24
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017	24
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study	24
Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis	24
Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review	23
A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT)	23
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder	23
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis	23
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis	23
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD	23
Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients	23
Home-Based Exercise Training in Multiple Sclerosis: A Systematic Review with Implications for Future Research	22
Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review✰	22
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS	22
To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection	22
Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis	22
Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder	22
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy	22
Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review	21
The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis	21
A pilot randomized controlled trial of robotic exoskeleton-assisted exercise rehabilitation in multiple sclerosis	21
“FLAMES: A novel burning entity in MOG IgG associated disease”	21
Normal antibody response after COVID-19 during treatment with cladribine	21
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis	21
Smartphone applications to assess gait and postural control in people with multiple sclerosis: A systematic review	21
¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis	21
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program	21
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies	21
Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder	21
How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey	21
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta	21
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS	21
High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics	21
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis	21
Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients	21
Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19	20
The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis	20
How personality traits affect functional outcomes in patients with multiple sclerosis: A scoping review on a poorly understood topic	20
Status of the neuromyelitis optica spectrum disorder in Latin America	20
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod	20
Predominant cognitive phenotypes in multiple sclerosis: Insights from patient-centered outcomes	20
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study	20
Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study	20
Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil	20
Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy	20
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial	20
Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders	20
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?	20
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis	20
Longitudinally extensive transverse myelitis following acute COVID-19 infection	20
The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis	19
Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study	19
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence	19
Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis	19
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses	19
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients	19
NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders	19
COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders	19
Blood levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): A systematic review and meta-analysis	19
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies	19
CNS demyelination during tofacitinib therapy: First report	19
Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis	19
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis	19
Challenges in multiple sclerosis care: Results from an international mixed-methods study	19
The psychological impact of Covid-19 pandemic on people with Multiple Sclerosis: A meta-analysis	19
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine	18
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis	18
A randomised controlled trial to test the feasibility of online mindfulness programs for people with multiple sclerosis	18
Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease	18
Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study	18
Depression mediates the relationship between fatigue and mental health-related quality of life in multiple sclerosis	18
Para-infectious anti-GD2/GD3 IgM myelitis during the Covid-19 pandemic: Case report and literature review	18
The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis	18
Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study	18
Fatigue and fluctuations in physical and psychological wellbeing in people with multiple sclerosis: A longitudinal study	18
Dual task training effects on gait and balance outcomes in multiple sclerosis: A systematic review	18

Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets	18
Prediction of unenhanced lesion evolution in multiple sclerosis using radiomics-based models: a machine learning approach	18
Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy.	18
Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.	18
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis	18
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID	17
Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis	17
Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies	17
Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)	17
Working ability in individuals with different disease courses of multiple sclerosis: Factors beyond physical impairment	17
A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder	17
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?	17
Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis	17
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study	17
Tenofovir as a treatment option for multiple sclerosis	17
Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies	17
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies	17
MRI signs of CNS demyelinating diseases	17
Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey	17
Human endogenous retrovirus and multiple sclerosis: A review and transcriptome findings	17
Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events	16
Frequency of comorbidities in Neuromyelitis Optica spectrum disorder	16
Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability	16
Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis	16
Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple sclerosis	16
Restless legs syndrome in people with multiple sclerosis: An updated systematic review and meta-analyses	16
Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light	16
COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis	16
Live birth rates, infertility diagnosis, and infertility treatment in women with and without multiple sclerosis: Data from an administrative claims database	16
Cyclophosphamide in treatment of tumefactive multiple sclerosis	16
Urinary tract infection in patients with multiple sclerosis: An overview	16
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes	16
What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)	16
A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis	16
Positive association of herpes simplex virus-IgG with multiple sclerosis: A systematic review and meta-analysis	16
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review	16
COVID-19 in a temporal relation to the onset of multiple sclerosis	16
The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment	16
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age	16
Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin	16
Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study	16
Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients	16
A serial mediation model of gratitude on life satisfaction in people with multiple sclerosis: The intermediary role of perceived stress and mental health symptoms	16
Brain MRI characteristics in neuromyelitis optica spectrum disorders: A large multi-center retrospective study in China	15
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS	15
Late onset multiple sclerosis is associated with more severe ventricle expansion	15
Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment	15
Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice	15
Employment status of people with multiple sclerosis in relation to 10-year changes in functioning and perceived impact of the disease	15
Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis	15
Are multiple sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic?	15
Could Sars-Cov2 affect MS progression?	15
The patients’ perspective on the perceived difficulties of dual-tasking: development and validation of the Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q)	15
Feasibility of a theory-informed mobile app for changing physical activity in youth with multiple sclerosis	15
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update	15
Clinical analysis of adult MOG antibody-associated cortical encephalitis	15
The role of language ability in verbal fluency of individuals with multiple sclerosis	15
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)	15
Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies	15
Coexistent MOG, NMDAR, CASPR2 antibody positivity: Triumph over the triumvirate	15
MRI features and evolution of autoimmune glial fibrillary acidic protein astrocytopathy: A retrospective cross-sectional and longitudinal study	15
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?	15
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions	15
Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases	15
The current status and challenges in multiple sclerosis management in the Philippines	15
The role of human endogenous retroviruses (HERVs) in Multiple Sclerosis and the plausible interplay between HERVs, Epstein–Barr virus infection, and vitamin D	15
Dietary factors and MRI metrics in early Multiple Sclerosis	15
Enlarged choroid plexus related to iron rim lesions and deep gray matter atrophy in relapsing-remitting multiple sclerosis	15
Optical Coherence Tomography in Neuromyelitis Optica spectrum disorder and Multiple Sclerosis: A population-based study	15
Reduced GABA levels in the medial prefrontal cortex are associated with cognitive impairment in patients with NMOSD	15
Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes	14
Smartphone based behavioral therapy for pain in multiple sclerosis (MS) patients: A feasibility acceptability randomized controlled study for the treatment of comorbid migraine and ms pain	14
Anti-NMDAR encephalitis may develop concurrently with anti-MOG antibody-associated bilateral medial frontal cerebral cortical encephalitis and relapse with elevated CSF IL-6 and CXCL13	14
Treatment of MOG-IgG associated disease in paediatric patients: A systematic review	14
Coping with stress during the first wave of the COVID-19 pandemic by Turkish people with Multiple Sclerosis: The relationship between perceived stress and quality of life	14
Transcutaneous spinal cord stimulation improves postural stability in individuals with multiple sclerosis	14
Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects	14
The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis	14
Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis	14
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination	14
Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study	14
Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis	14
Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?	14
A multidimensional approach to sleep health in multiple sclerosis	14
The impact of socioeconomic status on mental health and health-seeking behavior across race and ethnicity in a large multiple sclerosis cohort	14
Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis	14
Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis	14
Multiple sclerosis by phenotype in Germany	14
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitud	14
Functions of astrocytes in multiple sclerosis: A review	14
Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study	14
The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis	14
Multiple Sclerosis Data Alliance – A global multi-stakeholder collaboration to scale-up real world data research	14
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.	14
The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years	14